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Speed to clinic often does not allow for in-depth manufacturing process development and understanding of early 
phase clinical programs; however, this may be necessary when inconsistencies in process performance or 
product quality are observed. For a recent Phase 1 fed-batch process, drug substance manufacturing process 
variability was observed during development and manufacturing scale productions. Process performance 
variability was observed during upstream process with ending viability ranging from 90% to 60% and end 
product neutral glycan profile ranging from 15% to 50%. To mitigate future performance variability, two 
approaches were taken: 1) improve cell culture performance robustness and 2) probe the relationship between 
cell culture performance and product quality attributes. Using ambr®15 as a high-throughput screening tool, a 
series of risk-based process parameter screening studies were conducted to eliminate potential root causes for 
culture viability decline. Small scale studies, both at ambr®15 and benchtop bioreactor scales, offered insights 
suggesting shear sensitivity and raw material variability were potential contributors to inconsistent cell culture 
performance. Strategic process-specific alterations, such as changing aeration method and lowering the 
agitation intensity, resulted in culture health improvements. Small scale results also indicated high-risk medium 
lots may be identified and mitigated with additional shear protectants. Large scale manufacturing in-process 
data suggest glycosylation pattern may not be directly linked to cell culture viability. Further studies may be 
useful to identify other process steps that contribute to product quality variations. Learnings from this 
presentation highlight strategies to improve cell culture performance robustness and the need to establish the 
relationship between in-process attributes and end product quality.  
 
 
